This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Novartis Ag. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: C Daniel Meyers: Innovator in Non-Alcoholic Steatohepatitis Treatment
Introduction
C Daniel Meyers is a notable inventor based in Littleton, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of non-alcoholic steatohepatitis. His innovative work has led to the development of a patent that addresses this important health issue.
Latest Patents
C Daniel Meyers holds a patent for Licofligozin, which is aimed at the treatment, prevention, or delay of non-alcoholic steatohepatitis. This patent represents a crucial advancement in the medical field, providing new hope for patients suffering from this condition. The patent is officially recognized as 1 patent.
Career Highlights
Meyers is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on groundbreaking research and development projects that focus on innovative treatments for various diseases. His expertise and dedication have made him a valuable asset to the company.
Collaborations
Throughout his career, C Daniel Meyers has collaborated with esteemed colleagues such as Chinweike Ukomadu and Lloyd B Klickstein. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in medical research.
Conclusion
C Daniel Meyers is a distinguished inventor whose work in the treatment of non-alcoholic steatohepatitis has made a significant impact in the medical community. His contributions through his patent and collaboration with leading professionals highlight his commitment to advancing healthcare solutions.